Current drug therapies for pain include medicines like morphine, as well as aspirin and ibuprofen. While all of these decrease the sensation of pain, they also interact with other tissues such as the brain, heart and stomach, causing side effects.
Nav1.7 does not appear to be present in large quantities outside of the C-fibers of the spinal cord. As such, new drugs targeting this protein could herald a new class of pain treatments with many fewer side effects than our current drugs for pain.
Costa said she hopes to see a day where such a medicine would be available to her, providing her with full relief for the first time in her life.
For more information about Erythromelalgia, visit www.erythromelalgia.org. The Erythromelalgia Association (TEA) is a non-profit organization working to identify, educate, and support those suffering EM. Pamela Costa is a member of TEA.